Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis by unknown
Jiang et al. BMC Cancer 2013, 13:479
http://www.biomedcentral.com/1471-2407/13/479RESEARCH ARTICLE Open AccessGenetically engineered endostatin-lidamycin
fusion proteins effectively inhibit tumor growth
and metastasis
Wen-guo Jiang1,2, Xin-an Lu3,4, Bo-yang Shang1, Yan Fu3,4, Sheng-hua Zhang1, Daifu Zhou4, Liang Li1, Yi Li1,
Yongzhang Luo3,4* and Yong-su Zhen1*Abstract
Background: Endostatin (ES) inhibits endothelial cell proliferation, migration, invasion, and tube formation. It also
shows antiangiogenesis and antitumor activities in several animal models. Endostatin specifically targets tumor
vasculature to block tumor growth. Lidamycin (LDM), which consists of an active enediyne chromophore (AE) and a
non-covalently bound apo-protein (LDP), is a member of chromoprotein family of antitumor antibiotics with
extremely potent cytotoxicity to cancer cells. Therefore, we reasoned that endostatin-lidamycin (ES-LDM) fusion
proteins upon energizing with enediyne chromophore may obtain the combined capability targeting tumor
vasculature and tumor cell by respective ES and LDM moiety.
Methods: In this study, we designed and obtained two new endostatin-based fusion proteins, endostatin-LDP
(ES-LDP) and LDP-endostatin (LDP-ES). In vitro, the antiangiogenic effect of fusion proteins was determined by the
wound healing assay and tube formation assay and the cytotoxicity of their enediyne-energized analogs was
evaluated by CCK-8 assay. Tissue microarray was used to analyze the binding affinity of LDP, ES or ES-LDP with
specimens of human lung tissue and lung tumor. The in vivo efficacy of the fusion proteins was evaluated with
human lung carcinoma PG-BE1 xenograft and the experimental metastasis model of 4T1-luc breast cancer.
Results: ES-LDP and LDP-ES disrupted the formation of endothelial tube structures and inhibited endothelial cell
migration. Evidently, ES-LDP accumulated in the tumor and suppressed tumor growth and metastasis. ES-LDP and
ES show higher binding capability than LDP to lung carcinoma; in addition, ES-LDP and ES share similar binding
capability. Furthermore, the enediyne-energized fusion protein ES-LDP-AE demonstrated significant efficacy against
lung carcinoma xenograft in athymic mice.
Conclusions: The ES-based fusion protein therapy provides some fundamental information for further drug
development. Targeting both tumor vasculature and tumor cells by endostatin-based fusion proteins and their
enediyne-energized analogs probably provides a promising modality in cancer therapy.
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Antiangiogenesis is a promising approach to cancer ther-
apy. As known, several antiangiogenic agents are cur-
rently under investigation in clinical trials. In contrast to
those conventional therapies that kill tumor cells dir-
ectly, angiogenesis inhibitors suppress tumor growth by
blocking the formation of new blood vessels, which
provide oxygen and nutrients for tumor growth.
Endostatin (ES), a 20-kDa fragment cleaved from the
collagen XVIII COOH terminus that inhibits endothe-
lial cell proliferation and migration, is a well-known
angiogenesis inhibitor, which shows antiangiogenesis
and antitumor activities in several animal models. ES
inhibits 65 different tumor types and modifies 12%
of the human genome to down-regulate pathological
angiogenesis [1]. However, the mechanism and func-
tion of ES is still insufficient understanding. For anti-
angiogenic activity, ES appears to be dependent on
binding to E-selectin [2]. Also, ES blocks activity of
metalloproteinases 2, 9, and 13 [3]. ES may down-
regulate VEGF expression in tumor cells [4]. IGF-
II-mediated signaling and T-type Ca2+ channels also
involve the function of ES [5,6].
Shi et al. identified that cell surface nucleolin on an-
giogenic blood vessels is a functional receptor for ES,
and mediates the internalization and biological activities
of ES [7,8]. Mechanism studies by Huang et al. show
that vascular endothelial growth factor (VEGF) and
extracellular matrix (ECM) synergistically induce the
translocation of nucleolin from nucleus to cell surface
[9-11]. Previous studies show that ES specifically binds
to neovascular endothelial cells through its interaction
with the integrin receptors α5β1 and αVβ3, which has
been implicated in tumor metastasis [12,13]. A more re-
cent study shows that nucleolin and integrin α5β1 can
form a co-receptor for ES via UPAR on the endothelial
cell membrane [14]. ES labeled with a near-IR probe is
shown to selectively accumulate in the tumor site [15].
All these studies suggest that ES has a unique ability for
targeted cancer therapy.
However, like many angiogenesis inhibitors, ES single
administration didn’t achieve significant effects. The
clinical development ended in the U.S. in 2003 due to
limited efficacy and problems with protein formulation
and application [16]. Several studies reported the im-
proved selectivity and efficacy of chimeric molecules
comprised of toxins or other cytotoxic agents with
targeting agents on tumor vasculature, such as vascular
endothelial growth factor receptor-gelonin; Shiga-like
toxin-vascular endothelial growth factor fusion protein
and anti-TES-23 linked to neocarzinostatin [17-19]. So
the combination of the targeted and cytotoxic effects by
engineering two independent molecules sounds to be a
promising way for drug design.Lidamycin (LDM), also called C-1027, is a member of
chromoprotein family of antitumor antibiotics. The
LDM molecule consists of an enediyne chromophore
(AE) and a non-covalently bound apo-protein (LDP). It
was shown that the AE exerts extremely potent cytotox-
icity to cultured cancer cells, whereas the apo-protein
LDP keeps the labile enediyne relatively stable. The non-
covalently bound AE and LDP can be dissociated and
re-associated. The activity of rebuilt molecule remains as
potent as that of natural LDM. LDP, which is composed
of 110 amino acid residues, showed specific binding cap-
ability to various human tumor tissues and displayed
moderate cytotoxicity to Bel-7402 cells [20,21]. This spe-
cific binding capability and cytotoxicity of LDP implied
its potential use as a targeting drug carrier in the design
of new anticancer agents.
In order to combine the anti-angiogenic and cyto-
toxic functions of ES and LDM and to target both
tumor endothelial cells and tumor cells, we designed
two novel ES-based fusion proteins, ES-LDP and LDP-
ES and their enediyne-energized analogs, and then
detected their antitumor efficacies. Here we show that
ES-LDP fusion proteins should possess targeting prop-
erty of ES or LDP and moderate cytotoxicity effect of
LDP in addition to antiangiogenesis activity of ES and
the extremely potent cytotoxicity of the enediyne
chromophore of LDM when they were assembled.
Methods
Cells and cell culture
HMEC cell line was maintained in endothelial-specific
medium EBM-2 (Lonza, USA). The human lung carcinoma
PG-BE1 was routinely grown in RPMI-1640 (HyClone,
Beijing, China) supplemented with 10% fetal bovine serum
(Gibco, USA), 100 U/mL penicillin, and 100 μg/mL
streptomycin. The mouse breast cancer cell line 4T1 cells
expressing the firefly luciferase gene (4T1-luc) were pre-
served in our laboratory. For stable expression, the cells
were exposed to 500 μg/mL G418 (Gibco, USA). D-
luciferin was purchased from Xenogen (Alameda, CA).
Construction of the expression vectors
Two fusion proteins named LDP-ES and ES-LDP were
designed with an eight-amino acid-long linker (−GGG
SGGSG-) between LDP and ES. Each ES-based fusion
protein gene consists of the gene encoding LDP (110
amino acids; ref. 21), ES (184 amino acids; ref. 27), and
the linker peptide. After two rounds of PCR and DNA
cloning process, the resultant 909-bp fragment was
digested by NdeI/XhoI and was inserted into pET30a
expression vector to generate the expression plasmid.
DNA sequencing analysis (Invitrogen Corp.) was used
to verify that the gene was correct in sequence and had
been cloned in the frame.
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Cell migration was assessed in a wound-healing assay.
HMEC or 4T1 Cells at 5x105 cells per well were cul-
tured in 24-wells plate provided by the CytoSelect™
24-Well Wound Healing Assay Kit and allowed to proli-
ferate to form a confluent monolayer. The linear spacer
inserted in the well was removed, which created a re-
gular and defined “wound” within the cell monolayer.
Wash wells with media to remove dead cells and debris.
Wells were treated with different concentrations of ES,
ES-LDP or LDP-ES and further cultured until the con-
trol wound was fully closed at 37°C. Cells were fixed and
images were captured immediately at 40X magnification
from light microscopy and cells that migrated to the
scraped area were counted using Image-Pro Plus 6.0
software. Each experiment was performed twice, with
triplicate samples.
Tube formation assay
Formation of capillary tube like structures by HMEC
was assessed in Matrigel-based assay. Briefly, a 96-well
plate coated with 60 μl of Matrigel per well was allowed
to solidify at 37°C for 1 h. Cells (1.5 × 104 in 100 μl
medium) were added on each well and 100 μl of
medium containing different concentrations of ES, ES-
LDP or LDP-ES were added and incubated for different
periods of time. Each treatment was performed in tripli-
cate. The enclosed networks of tubes were photographed
under microscope. The total tube lengths and numbers
of the tube structure of each photograph were measured
using Image-Pro Plus 6.0 software.
Immunohistochemistry in tissue microarray
Multiple arrays of formalin-fixed, paraffin-embedded lung
tumors and normal lung tissue were obtained from U.S.
Biomax, Inc. (Xi’an, China). The microarray of product
number BC041115a contains 110 lung tumors and un-
matched normal lung tissue (10 cases/type). The normal
controls were derived from the same organ but not from
the same patient. The array dot diameter was 0.6 mm. All
immunohistochemical studies were performed on paraffin-
embedded sections as previously described [21]. For
Cetuximab controls, the tissue sections were stained in the
same manner except that the detection antibody was re-
placed with poly-HRP-anti-human IgG against Cetuximab.
The positive percentage of each protein could be calcu-
lated according to the staining intensity by reference to
the Herceptest™ interpretation manual.
Additionally, we analyzed the cases by Image-Pro Plus
6.0 software, using the method introduced by Xavier
et al. [22,23]. Briefly, the measurement parameters in-
cluded density mean, area sum, and integrated optical
density (IOD). The optical density was calibrated and the
area of interest was set through: hue, 0 ~ 30; saturation,0 ~ 255; intensity, 0 ~ 255, then the image was converted
to gray scale image, and the values were counted. The
time required to perform the analysis process can be
greatly reduced by using macro of pathology. To avoid
artificial effect, cells in areas with necrosis, poor morph-
ology, or in the margins of sections were not taken into
account. The IOD were log transformed and mainly
performed statistical analysis.
Preparation of enediyne-energized ES-LDP and LDP-ES
The active enediyne chromophore (AE) of LDM was
separated by using C4 column (GE Healthcare) with a
22% acetonitrile in 0.05% trifluoroactic acid mobile
phase. The AE-containing solution was added to ES-
LDP/PBS (10 mmol/L; pH7.4) or LDP-ES/PBS, respect-
ively, with the molecular ratio of 4:1, and was incubated
at 4°C for12 h while rocking. Free AE was removed by
using a Sephadex G-75 column (GE Healthcare). Assem-
bled enediyne-energized fusion proteins named LDP-ES-
AE and ES-LDP-AE were confirmed by reverse-phase
HPLC using a Vydac C4 300A column (Grace). Absor-
bance at 340 nm was measured.
Cell cytotoxicity assay by cell counting kit-8
Cells were seeded at 1 × 104 per well in 96-well plates
and incubated in 37°C for 24 h and then exposed to dif-
ferent concentrations of LDM or energized fusion pro-
teins (ES-LDP-AE, LDP-ES-AE) for 48 h. On the day of
measuring the growth rate of cells, 100 μL of spent
medium was replaced with an equal volume of fresh
medium containing 10% CCK-8 (WST-8, Dojindo La-
boratories, Tokyo, Japan). Cells were incubated at 37°C
for 1 h, and cell number was assessed by measuring the
absorbance at 450 nm on a microplate reader (Thermo).
Three independent experiments were carried out. The
IC50 represented the drug concentration resulting in
50% growth inhibition.
Tumor models
The syngeneic murine 4T1-luc breast cancer model and
human lung carcinoma PG-BE1 xenograft model have
been used. The BALB/c female mice and female athymic
nude mice (BALB/c, nu/nu) were purchased from the
Institute for Experimental Animals, Chinese Academy of
Medical Sciences & Peking Union Medical College. The
study protocols were in accordance with the regulations
of Good Laboratory Practice for non-clinical laboratory
studies of drugs issued by the National Scientific and
Technologic Committee of People’s Republic of China.
The treatment and use of animals during the study was
approved by the Animal Ethics Committee of the Insti-
tute of Medicinal Biotechnology, Chinese Academy of
Medical Sciences & Peking Union Medical College (per-
mission number: c1-2011-1121).
Figure 1 Construction and preparation of endostatin-lidamycin
fusion proteins. Diagram of fusion proteins: LDP-ES (top) and ES-LDP
(middle); Bottom, the amino acid sequence of the linker (A). (B)
SDS-PAGE and (C) Western blotting detection of the expression of
fusion proteins. Lane 1, molecular weight marker; Lane 2, empty
vector as a control; Lane 3 and Lane 4, vector expressing LDP-ES; Lane
5 and Lane 6 vector expressing ES-LDP. Arrow indicates the bands of
fusion proteins. The enediyne-energized fusion proteins determined
by reverse-phase HPLC on C4 300A column at 340 nm (D).
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cells were implanted into the 16–18-week-old female
athymic nude mice by the subcutaneous injection of
10 × 106 cells on the right flank. After 3 weeks, the tu-
mors were aseptically dissected and pieces of tumor tis-
sue (2 mm3 in size) were transplanted s.c. separately by
a trocar into athymic mice. When tumors reached about
100 mm3 in size, the mice were randomized into groups
(n = 6 per group) and treated with ES,LDM,ES-based fu-
sion proteins (ES-LDP, LDP-ES) and energized fusion
proteins (ES-LDP-AE, LDP-ES-AE), respectively, at dif-
ferent doses and time intervals. Tumor growth was mea-
sured with a caliper, and tumor volumes were calculated
with the following formula: V = 0.5a × b2, where a and b are
the long and the perpendicular short diameters of the
tumor, respectively. Typically, studies were terminated when
tumors in the control animals reached an average size of
2000 mm3. Percentage of inhibition of tumor growth was
calculated as 100 × {1-[(tumor volumefinal-tumor volumeinitial
for the treated group)/(tumor volumefinal-tumor volumeinitial
for the vehicle-treated group)]}.
We studied the lung metastasis of tumors using an i.v.
injection model. BALB/c female mice were injected with
2 × 105 murine 4T1-luc breast cancer cells in 0.2 mL PBS
solution via the lateral tail vein. Three days later after
tumor cell injection, mice were randomly assigned to three
groups and treated with ES or ES-LDP respectively. Seven
days after the first treatment, all mice were injected again
at same doses. After 17 days, Mice were anesthetized with
isoflurane and i.p. injected with luciferase substrate D-
luciferin (150 mg/kg). The animals were placed onto the
warmed stage inside the camera box (IVIS-Imaging Sys-
tem, Xenogen) to observe tumor growth. Then, the lungs
were immediately removed, weighed and fixed in 10%
buffered formalin for counting of pulmonary metastatic
nodules. The metastatic nodules of 4T1 tumor in lung
were counted by direct visualization using a stereomicro-
scope. The total number of metastases per lung section
was counted and averaged among the animals.
In vivo fluorescence imaging
When tumors reached about 200 mm3 in size in human
PG-BE1 xenograft model, three hundred micrograms of
DyLight 680-labeled ES-LDP or LDP-ES were injected
i.v. (n = 3). The mice were placed under anesthesia by in-
halation of isoflurane and the images were observed with
the Xenogen Ivis 200 system and recorded by built-in
camera (Caliper Life Sciences).
Statistical analysis
All of the data were presented as the mean ± SD for at
least three independent experiments. Statistical analysis
was performed with SPSS software (version 17.0). The
significant differences between any of two groups wereevaluated by One-way ANOVA. Statistical significance
was defined as P < 0.05.
Results
Construction, preparation and biochemical
characterization of ES-LDP, LDP-ES and their enediyne-
energized analogs
DNA fragments encoding LDP and ES fusion proteins
were obtained by PCR and molecular cloning tech-
niques. As shown in Figure 1A, LDP-ES and ES-LDP
were designed with an eight-amino acid-long linker be-
tween LDP and ES. The DNA fragments encoding
these two fusion proteins were cloned and inserted into
the pET30a expression vector. SDS-PAGE (Figure 1B)
and Western blotting (Figure 1C) were used to detect
the expression of fusion proteins. The energized fusion
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LDM into ES-LDP and LDP-ES, respectively. Data from
reverse-phase HPLC showed that AE molecule was suc-
cessfully integrated into fusion proteins (Figure 1D), which
implies that LDP keeps its native structure in fusion pro-
teins. The assembling efficiency of ES-LDP and LDP-ES
was 83.9% and 27.1%, respectively (data not shown).
In CCK-8 assay, LDP-ES-AE or ES-LDP-AE displayed
extremely potent cytotoxicity to kinds of cancer cells
and endothelial cells in proximity to that of free LDM,
as shown in Table 1. The IC50 values ranged from 10-9
M to 10-10 M and all cell lines were relatively more sen-
sitive to ES-LDP-AE than to LDP-ES-AE, which may re-
sults from the relatively lower assembling efficiency of
AE in LDP-ES.
ES-LDP and LDP-ES inhibited HMEC and 4T1 cells
migration in wound healing assay
New blood vessel formation requires that the endothelial
cells migrate towards the sources of growth factor. We
used the HMEC wound healing assay to observe the abil-
ity of ES-based fusion proteins in inhibiting endothelial
cell migration. As shown in Figure 2A, cells were able to
migrate towards the wound area in higher number when
exogenous rhVEGF was added. ES or ES-based fusion
proteins all demonstrated the ability of inhibiting HMEC
migration at different concentrations when compared
with rhVEGF control (Figure 2A). Comparison of quanti-
fied results shows that ES-based fusion proteins are more
potent than ES, and ES-LDP exhibits a stronger inhibitory
effect than LDP-ES (Figure 2B). These results indicate
that ES-based fusion proteins have increased capability in
inhibiting VEGF-induced endothelial cell migration.
Since 4T1 cells were reported to metastasize to the
lung, liver, bone, and brain via the hematogenous route
[24], we therefore examined effects of ES-based fusion
proteins on 4T1 cell migration in vitro and observed si-
milar phenomena with those in HMEC wound healing
assay. As can be seen in Figure 2C and 2D, both low
(1 μM) and high (10 μM) concentrations of fusion pro-
teins markedly suppressed the migration of 4T1 cells.
Interestingly, it appears that 4T1 cells are more sensitive
than HMECs to ES and ES-based fusion protein treat-
ments, and that all the proteins tested inhibited cell mi-
gration in a dose dependent manner (Figure 2).Table 1 Determined IC50 values for enediyne-energized
fusion proteins in HMEC and different cancer cell lines
Cells IC50(M)
HMEC PG-BE1 4T1
LDM 1.16 ± 0.39 × 10-10 1.01 ± 0.24 × 10-9 2.79 ± 0.41 × 10-10
ES-LDP-AE 8.13 ± 0.98 × 10-10 8.06 ± 2.06 × 10-10 2.05 ± 0.67 × 10-10
LDP-ES-AE 1.14 ± 0.39 × 10-9 2.61 ± 0.14 × 10-9 2.94 ± 0.80 × 10-9ES-LDP and LDP-ES disrupted endothelial tubule formation
An endothelial tubule formation assay was used to fur-
ther confirm the antiangiogenic activity of the fusion
proteins. In this experiment, the use of Matrigel permits
the growth and differentiation of endothelial cells into
tubal structures that are reminiscent of blood vessels.
Prominent tubal structures were observed in control cells
(Figure 3A). ES or ES-based fusion proteins inhibited tube
formation of HMEC in a concentration-dependent man-
ner. At the low concentration (1 μM; Figure 3A, left col-
umn) ES or ES-based fusion proteins began to disrupt the
formation of the tubes, as indicated by the arrows. At the
high concentration (10 μM; Figure 3A, right column), ES
or ES-based fusion proteins eliminated the tubal struc-
tures. As shown in Figure 3B and 3C, ES or ES-based fu-
sion proteins reduced the number of closed capillary
tubes as well as their length.
In vivo targeting of ES-LDP and LDP-ES
Since ES was reported to specifically target tumor tissues
[15], and fusion proteins are supposed to inherit distri-
butional specificity, in vivo distribution of DyLight 680-
labeled ES-LDP or LDP-ES was observed in nude mice
bearing human PG-BE1 xenograft.
As expected, ES-LDP protein accumulated into the
tumor area and reached the highest level within 1 h after
injection and then gradually cleared from the tumor area
during the following 3 hours (Figure 4, Upper). Surpris-
ingly, DyLight 680-labeled LDP-ES showed little accu-
mulation in PG-BE1 tumor, but a random distribution in
the whole body followed by a normal clearance process
(Figure 4, Lower). However, this observation is consist-
ent with our previous result obtained with LDP [25],
which indicates that fusion LDP to the N-terminus of ES
does not improve the targeting of LDP.
Binding of ES-LDP to lung tumors and normal lung tissues
Based on the ES-LDP accumulation in human lung car-
cinoma PG-BE1, we tested the binding capability of LDP,
ES and ES-LDP through tissue microarray of human lung
tissues. The number of spots that can be interpreted was
117 from total 120 core samples (3 normal tissue cores
were missed). Cetuximab was used as a control to ensure
criterion of tissue microarray (Figure 5A). The representa-
tive examples of LDP, ES or ES-LDP staining were shown
in Figure 5B. The positive percentage of ES and ES-LDP
was higher than that of LDP (P < 0.001, χ2 test; Table 2).
The difference of ES-LDP binding capability between the
tumor tissue and normal tissue samples was significant
(P < 0.05, χ2 test; Table 2). Additionally, the IOD value of
Image Pro-Plus analysis was representative parameter to
assess the immunohistochemistry quantification, and in-
creased sensitivity in scoring and provided a more reliable
and reproducible analysis of protein expression and
Figure 2 HMEC and 4T1 migration in wound healing assay using ES or ES-based fusion proteins as inhibitors. Pictures were taken at
magnification 40X in light microscopy (A and C). Quantification results of migrated cells, counted using the software Image-Pro Plus 6.0, are
shown in B and D, assuming control as 100%. Inhibitors were used at indicated concentration. Results shown are average values of 6
representative fields in each of the two different experiments performed in duplicates, and error bars represent SEM. *, P≤ 0.05, **, P≤ 0.001,
compared with ES, respectively. Cells were viewed with a microscope and pictures were taken at × 40.
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respectively. The differences of IOD were significant be-
tween LDP and ES, as well as between LDP and ES-LDP
(P < 0.0001). However, the difference between ES and ES-
LDP was not significant (P > 0.05, Table 2).
ES-LDP, LDP-ES and their enediyne-energized analogs
inhibited tumor growth
Since ES-LDP and LDP-ES show dramatic difference in
tumor targeting in vivo, we are thus curious about their
antitumor efficacies. The in vivo efficacies of ES-based
fusion proteins and their enediyne-energized forms were
tested by two separate experiments with human lung
carcinoma PG-BE1 xenograft in athymic mice.
In the first experimental setting, the mice bearing PG-
BE1 xenografts were divided into four groups and were
treated with ES, ES-LDP, and LDP-ES, through intraperi-
toneal injection every other day in a total of 7 injections,
respectively. ES was given at the dose of 12 mg/kg, and
ES-LDP or LDP-ES was given at a dose of 18 mg/kg to
meet the equal molar concentration with ES. Control
mice received equal volume of saline. Determined by ex-
ternal measurement of tumor volume (twice per week),
tumor growth was suppressed in ES and ES-LDP groups
as compared with control mice over the whole period of26 days. As evaluated on day 23, the inhibition rates of
tumor growth for ES and ES-LDP were 24.5% and
30.2%, respectively, indicating moderate antitumor effi-
cacies against the lung carcinoma PG-BE1 xenograft. By
contrast, LDP-ES appeared to be less effective. Figure 6A
shows the tumor growth curve of each group. Figure 6C
shows the changes in body weight after treatment with
ES and the fusion proteins, in which no significant dif-
ference was observed among the groups.
In a separate animal study, the antitumor activity of
enediyne-energized fusion protein was investigated. PG-
BE1 xenografts bearing mice were treated with LDM,
ES-LDP-AE or LDP-ES-AE, respectively. LDM was given
at a well-tolerated dose of 0.05 mg/kg. Because of the
different enediyne assembly efficiency, ES-LDP-AE was
given at the doses of 0.15 and 0.30 mg/kg; whereas LDP-
ES-AE was given at the doses of 0.30 and 0.60 mg/kg,
respectively. Mice received intravenous injection of
LDM, ES-LDP-AE or LDP-ES-AE once a week for twice,
and tumor volumes were measured during the treat-
ment. It was shown that both energized fusion proteins
have remarkable inhibitory effect on the growth of PG-
BE1 xenografts (Figure 6B). Mice receiving LDM at 0.05
mg/kg showed an inhibition rate of 61.1%, while ES-
LDP-AE (0.15 mg/kg) and LDP-ES-AE (0.60 mg/kg) at
Figure 3 ES, ES-LDP or LDP-ES inhibited in vitro tubule formation. (A) ES or ES-based fusion proteins inhibited tubule formation of HMEC on
Matrigel. Low (1 μM) and high (10 μM) concentrations were used. Bar, 200 μm. (B) Mean capillary tube number and (C) mean tube length was
decreased by ES and ES-based fusion proteins after 12-h incubation. Three arbitral optical images were taken for each of the two independent
experiments. Data are expressed as mean and standard deviation from six independent images, n = 6. *, P≤ 0.05, **, P≤ 0.001, compared with
VEGF-control and #, P≤ 0.05, compared with ES, in tube length and tube number, respectively. Cells were viewed with a microscope and pictures
were taken at × 40.
Figure 4 Optical imaging in living animal using DyLight 680-labeled ES-LDP or LDP-ES. Color scale represents photons/s/cm2/steradian, the
red dot-cycle indicated the tumor location.
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Figure 5 Lung tissue microarray. (A) Representative examples of HE staining (a); no staining (b), weak staining (c) and strong staining (d) for
Cetuximab; (B) Representative examples of LDP, ES or ES-LDP staining. First row: normal human lung tissues with ES positive staining. Second
row: lung tumor tissues with ES and ES-LDP positive. Original magnification was 40 × .
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growth by 78.5% and 75.8% (P < 0.01, vs LDM), respect-
ively (Figure 6B). Furthermore, the ES-LDP-AE-treated
group at 0.30 mg/kg, inhibited tumor growth by 86.4%,
showing significant difference (P < 0.01, vs LDM) com-
pared with LDM-treated group at 0.05 mg/kg tolerated
dose. Body weight loss resulted from the enediyne-
energized fusion proteins treatment in each group was
also measured at the termination of the experiment, in
which all groups except ES-LDP-AE-treated group at 0.30
mg/kg did not exceed 10% of the pretreatment weights.
No deaths were found in all treated groups (Figure 6D).
ES-LDP inhibited tumor metastasis
Because ES-LDP fusion protein was found to markedly
suppress the migration of 4T1 cells in vitro, the anti-
metastatic effect of ES-LDP was further evaluated with the
lung metastasis model of 4T1-luc tumors. ES-LDP wasTable 2 Summary analysis and comparison of proteins
binding capability in lung tissue microarray






(Mean ± SD) (Mean ± SD)
LDP 44.9 6.59 ± 0.31 50 6.33 ± 0.28
ES 94.4## 7.21 ± 0.23** 90 6.59 ± 0.19
ES-LDP 87.5## 7.03 ± 0.28** 60^ 6.39 ± 0.18
** P ≤ 0.001, vs LDP (One-way ANOVA test).
## P ≤ 0.001, vs LDP (χ2 test).
^ P ≤ 0.05, vs lung tumor (χ2 test).administered through i.v. injections. Significant differences
in lung colonization were found among the ES-treated
group, ES-LDP-treated group and the untreated control
group (Figure 7A). In addition, ES-LDP treatment sig-
nificantly reduced the number of surface metastasis
(51.4%) and lung weight gain (56.7%) in tumor-bearing
animals compared to the untreated animals (Figure 7B
and 7C). By contrast, ES decreased the number of sur-
face metastasis and lung weight gain only by 35.2% and
34.2%, respectively.
Discussion
ES, an angiogenesis inhibitor having been tested in multiple
clinical trials, selectively targets endothelial cells in
neovascularization and suppresses tumor growth. However,
like other angiogenesis inhibitors, such as bevacizumab,
sunitinib and sorafenib, ES could help patients to survive
longer when given in combination with chemotherapy, but
not when given alone [26]. To enhance the therapeutic
efficacy of ES, several ES derivatives with different modifica-
tions have been designed, which include ES-cytosine deami-
nase protein, prolactin antagonist-ES, anti-HER2 IgG3-ES,
ZBP-ES (Endostar), Fc-ES, and cell-permeable ES protein
(HM73ES) [27-32].
The ES-cytosine deaminase protein, which converts a
non-cytotoxic prodrug 5-fluorocytosine (5-FC) to the cyto-
toxic antitumor drug 5-fluorouracil (5-FU) in the local
tumor area, significantly inhibited the growth of endothe-
lial cells and preferentially induced tumor cell apoptosis
[28]. The prolactin antagonist-ES fusion protein is a bi-
functional protein, which inhibits both breast cancer cell
Figure 6 In vivo efficacies of ES-based fusion proteins and the enediyne-energized fusion proteins on PG-BE1 xenograft models. In
experiment 1 (Exp 1), nude mice bearing human lung carcinoma PG-BE1 xenografts were treated with ES, ES-LDP or LDP-ES i.p. injections at
different doses (n = 6). Mean tumor volumes (A) and mean body weights of mice (C) in each group are shown. Arrows indicate the day of
injection (every other day). In experiment 2 (Exp 2), nude mice bearing PG-BE1 xenografts were treated with LDM, LDP-ES-AE, or ES-LDP-AE
(n = 6), i.v. injections respectively. Mean tumor volumes (B) and mean body weights of mice (D) in each group are shown. Arrows indicate the
day of injection (day 9 and 15).
Figure 7 ES-LDP treatment inhibits the lung metastasis of 4T1-luc tumors. 4T1-luc cells (2 × 105) were injected intravenously into mice. Mice
were given ES (36 mg/kg body weight) or ES-LDP (54 mg/kg body weight) twice, and saline served as control. At the end of the experiment,
mice were injected with D-luciferin and bioluminescence imaging was done. Then, animals were killed and lungs were harvested and weighed
before evaluation of the surface metastasis. (A) The profile of optical imaging from different experimental groups. ES-LDP-treated mice showed
both significantly reduced surface metastasis (B) and lung weight gain (C) in comparison to the control animals. (* P < 0.05,** P < 0.01; compared
to control, respectively).
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greater tumor inhibitory effects than prolactin antagonist
and ES treated individually or in combination [29].
Targeting of ES using anti-HER2 antibody and human ES
fusion protein could improve antitumor activity of either
anti-HER2 antibody and/or ES and provides the versatile
approach that could be applied to other tumor targets with
alternative antibody specificities [30]. ZBP-ES, engineered
by adding 9 extra amino acid residues MGGSHHHHH to
the N-terminus of ES, showed increased thermodynamic
stability and biological activity than the wild type ES [27],
and was approved as anti-cancer drug in China. As
reported, Fc-ES is a superior molecule to the original clin-
ical ES. Due to its long half-life, the amount of protein re-
quired is substantially reduced compared with the
clinically tested ES [31]. HM73ES exhibited enhanced tis-
sue penetration and suppressed the growth of human
tumor xenografts to a significantly greater extent than un-
modified ES by adding a macromolecule transduction do-
main (MTD). Those results suggest another important
mechanism to explain the enhanced activity of ZBP-ES
and ES lacking the MTD sequence [32].
Recent studies indicated that LDP itself, the apopro-
tein of LDM, shows binding capability to a spectrum of
human tissues, and notably that the binding capability
correlates with the overexpression of EGFR and HER2 on
the tumor tissue microarray [21]. In addition, LDP
displayed moderate cytotoxicity to human hepatoma Bel-
7402 cells with an IC50 value of 7.05 × 10-5 mol/l and it
exerted tumor suppression on hepatoma H22 in Kunming
mice [20]. The functional receptor of ES nucleolin was
found to be specifically expressed on the surface of angio-
genic blood vessels in tumor tissues, which endows ES
low toxicity and tumor-specific distribution [7]. There-
fore, in the present study, we constructed and prepared
two ES-based fusion proteins ES-LDP and LDP-ES. Our
results indicate that ES-LDP and LDP-ES disrupted the
formation of endothelial tubule structures with the po-
tency similar to that of ES. In addition, ES-based fusion
proteins, especially ES-LDP, demonstrated much stronger
inhibition of HMEC migration than ES. Furthermore, ES-
LDP displayed high efficacy in PG-BE1 xenografts. This
may be explained by the reason that N-terminal loop of
ES around the zinc-binding site was involved in activity
[33], and that the N-terminal integrity is essential for the
biological functions of ES [27]. So it appears that the anti-
tumor activity of ES could be enhanced by integrating
with LDP and a free N-terminus of ES in the fusion pro-
tein is preferred. But its mechanism should be studied
further, and there is more work to be done.
On the other hand, angiogenesis is involved in the de-
velopment of distant metastasis. Thus by targeting angio-
genesis, ES directly suppresses not only the growth of
primary tumors but also metastasis. The present studyhas shown that ES-LDP or LDP-ES could markedly in-
hibit 4T1 cells migration in wound healing assay, with
ES-LDP exhibiting a more potent activity. Therefore, we
examined the effects of ES-LDP on the lung metastasis of
4T1-luc tumors. ES-LDP treatment significantly reduced
the number of lung surface metastasis and lung weight
gain in tumor-bearing animals. Therefore, ES-LDP could
be explored as a novel therapeutic molecule in controlling
metastasis of cancer.
LDM is considered as a highly potent “warhead” mol-
ecule for the construction of antibody-based tumor
targeting drugs. At present, several LDM-containing ener-
gized fusion proteins have been manufactured with the
two-step procedure in our laboratory, such as bispecific
enediyne-energized fusion protein (Ec-LDP-Hr-AE) and
tandem scFv-based enediyne-energized fusion protein
(dFv-LDP-AE) [25,34]. Both of them possessed highly po-
tent cytotoxicity to cancer cells and significant inhibitory
efficacy in vivo. Ec-LDP-Hr-AE was more potent and se-
lective in its cytotoxicity against different carcinoma cell
lines in vitro and significantly inhibited the growth of SK-
OV-3 xenografts in nude mouse model [34]. dFv-LDP-AE
displayed extremely potent cytotoxicity to kinds of cancer
cells, especially the lung cancer cell lines, and greatly in-
creased the antitumor efficacy with lung carcinoma PG-
BE1 xenograft in nude mice [25].
We adopted a strategy to energize the ES-based fusion
proteins, ES-LDP and LDP-ES, with LDM enediyne
chromophore to prepare ES-based and enediyne-
energized fusion proteins (ES-LDP-AE and LDP-ES-AE).
They all displayed potent antitumor activities against a
variety of tumor cell lines with IC50 values ranged from
10-9 M to 10-10 M. Though the IC50 values had ten-fold
difference, the IC50 value of ES-LDP-AE was always less
than that of LDP-ES-AE. This difference may be due to
the assembling efficiency of ES-LDP and LDP-ES, which
was 83.9% and 27.1%, respectively. These results accord
with assembling efficiency, and potential conformational
change of the AE binding sites caused by the fusion. In
the in vivo study, mice received tolerated dose of LDM
at 0.05 mg/kg showed an inhibition rate of 61.1%. By
contrast, ES-LDP-AE and LDP-ES-AE at equivalent
doses suppressed the tumor growth by 78.5% and 75.8%,
respectively. Furthermore, the ES-LDP-AE-treated group
at higher dosage of 0.30 mg/kg showed an inhibition rate
of 86.4%. No deaths were found in all treatment groups.
As previously mentioned, ES has a unique ability for
targeting therapy of cancer [15]. Endostar is now in clin-
ical use for lung cancers in China, so we investigated the
affinity of these ES-based fusion proteins to human lung
cancers by tissue-microarray analysis. As shown, the
positive percentage of ES and ES-LDP was higher than
that of LDP; in addition, ES and ES-LDP share similar
binding capability to lung cancer tissue, indicating that
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the ES. It is of interest that the integration of LDP into
the fusion protein ES-LDP does not compromise ES
binding capability, while probably provides a targeting
delivery of lidamycin.
Conclusions
The ES-based fusion protein therapy provides some fun-
damental information for further drug development.
Endostatin-lidamycin (ES-LDM) fusion proteins upon
energizing with enediyne chromophore obtain the com-
bined capability targeting tumor vasculature and tumor
cell by respective ES and LDM moiety. Targeting both
tumor vasculature and tumor cells by endostatin-based
fusion proteins and their enediyne-energized analogs
probably provides a promising cancer therapy.
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